N

EW YORK — Moderna Therapeutics, biotech’s most richly valued and hotly debated startup, made headlines Thursday morning with a cheery update on its pipeline of futuristic medicines.

Hours later, about 100 of biotech’s top investors and analysts packed into a ballroom at Manhattan’s tony W Hotel for a closed-door presentation they hoped would take them behind the press release — and tell them whether Moderna truly deserves its $5 billion valuation.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.